Zealand Pharma’s IND for ZP1846 Approved by FDA

FDA has approved Zealand Pharma A/S' Investigative New Drug application, IND, for ZP1846 to be administered in humans. ZP1846 is developed for the prevention and treatment of severe diarrhoea induced by chemotherapy.

The Phase I study will be a double-blind, placebo controlled, randomized, escalating intravenous single dose safety and tolerability study in healthy volunteers and takes place in the United States.

Zealand's pre-clinical studies have demonstrated that ZP1846 inhibits chemotherapy-induced injury in the small intestine, and consequently, it also reduces the incidence of chemotherapy-induced diarrhoea. It is anticipated that the use of ZP1846 in patients undergoing chemotherapy may ameliorate the destructive effects of the chemotherapy on the small intestine and reduce the severity of diarrhoea.

For further information please contact:

Mogens Vang Rasmussen,

Chief Financial Officer

Tel: +45 43 28 12 00

Email: info@zp.dk

Or visit: www.zp.com